The DOI matches its Crossref record.
Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure
Abstract
Recent studies implicate increased cGMP synthesis as a postreceptor contributor to reduced cardiac sympathetic responsiveness. Here we provide the first evidence that modulation of this interaction by cGMP‐specific phosphodiesterase PDE5A is also diminished in failing hearts, providing a novel mechanism for blunted β‐adrenergic signaling in this disorder. In normal conscious dogs chronically instrumented for left ventricular pressure‐dimension analysis, PDE5A inhibition by EMD82639 had modest basal effects but markedly blunted dobutamine‐enhanced systolic and diastolic function. In failing hearts (tachypacing model), however, EMD82639 had negligible effects on either basal or dobutamine‐stimulated function. Whole myocardium from failing hearts had 50% lower PDE5A protein expression and 30% less total and EMD92639‐inhibit‐able cGMP‐PDE activity. Although corresponding myo‐cyte protein and enzyme activity was similar among groups, the proportion of EMD82639‐inhibitable activity was significantly lower in failure cells. Immunohis‐tochemistry confirmed PDE5A expression in both the vasculature and myocytes of normal and failing hearts, but there was loss of z‐band localization in failing myocytes that suggested altered intracellular localization. Thus, PDE5A regulation of cGMP in the heart can potently modulate β‐adrenergic stimulation, and alterations in enzyme localization and reduced synthesis may blunt this pathway in cardiac failure, contributing to dampening of the β‐adrenergic response.—Senzaki, H., Smith, C. J., Juang, G. J., Isoda, T., Mayer, S. P., Ohler, A., Paolocci, N., Tomaselli, G. F., Hare, J. M., Kass, K. A. Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure. FASEB J . 15, 1718—1726 (2001)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
Takimoto, E., Champion, H. C., Li, M., Belardi, D., Ren, S., Rodriguez, E. R., Bedja, D., Gabrielson, K. L., Wang, Y., & Kass, D. A. (2005) · Nature Medicine · doi:10.1038/nm1175 · Cited by 903
Self-citationOverview of PDEs and Their Regulation
Omori, K., & Kotera, J. (2007) · Circulation Research · doi:10.1161/01.res.0000256354.95791.f1 · Cited by 796
Michelakis, E., Tymchak, W., Lien, D., Webster, L., Hashimoto, K., & Archer, S. (2002) · Circulation · doi:10.1161/01.cir.0000016641.12984.dc · Cited by 577
Nagendran, J., Archer, S. L., Soliman, D., Gurtu, V., Moudgil, R., Haromy, A., St. Aubin, C., Webster, L., Rebeyka, I. M., Ross, D. B., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.655266 · Cited by 530
Lewis, G. D., Shah, R., Shahzad, K., Camuso, J. M., Pappagianopoulos, P. P., Hung, J., Tawakol, A., Gerszten, R. E., Systrom, D. M., Bloch, K. D., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.716373 · Cited by 515
Metadata
- Authors
- SENZAKI, H., SMITH, C. J., JUANG, G. J., ISODA, T., MAYER, S. P., OHLER, A., PAOLOCCI, N., TOMASELLI, G. F., HARE, J. M., & KASS, D. A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2001-08
- Volume
- 15
- Issue
- 10
- Pages
- 1718-1726
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1995896668
- Cited by
- 228
- References
- 0
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure. https://app.cochat.ai/papers/10.1096/fj.00-0538com
- The paper
- SENZAKI, H., SMITH, C. J., JUANG, G. J., ISODA, T., MAYER, S. P., OHLER, A., PAOLOCCI, N., TOMASELLI, G. F., HARE, J. M., & KASS, D. A. (2001). Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure. The FASEB Journal. https://doi.org/10.1096/fj.00-0538com
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.